瑞科生物-B(02179)今日盘中股价大幅下挫，跌幅达到25.00%，引发市场关注。
消息面上，公司于今日盘前发布了截至2025年12月31日止的年度业绩。财报显示，公司股东应占亏损为6.1亿元人民币，较上年同期的5.62亿元亏损进一步扩大8.54%，每股亏损1.15元人民币，且本次不派发股息。业绩不及预期，是导致股价承压大跌的主要原因。
尽管公司在公告中介绍了其丰富的疫苗产品管线，包括处于上市申请阶段的新佐剂重组带状疱疹疫苗REC610，以及处于III期临床试验阶段的重组九价HPV疫苗REC603，并强调了其技术平台和生产能力，但市场焦点仍集中在亏损扩大的财务表现上，投资者信心因此受挫。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.